Board of Directors
Russell Siegelman has spent over twenty years in business and technology as a manager, investor and director. As a Lecturer at Stanford Business School he teaches Startup Garage, Product Launch and Starting and Growing a Social Venture. Starting in 1996, Russell spent eleven years as a Partner at Kleiner Perkins Caufield & Byers, where he invested in consumer and technology related technologies and markets, including software, electronic commerce, Web services, semiconductors, mobile systems, media and telecommunications.
Russell joined KPCB after seven years at Microsoft. At Microsoft he helped launch LAN Manager, Microsoft’s first network operating system, then was the marketing manager in charge of Windows for Workgroups, a small-business networking version of Windows. For the first half of 1993, Russell worked directly for Bill Gates, during which time he researched the online market and recommended an entry strategy for that market. This led to the formation the Microsoft Network (MSN), Microsoft’s online service. Russell became the first employee of this division and became its General Manager and then Vice President through April of 1996. Under his direction, MSN was developed and launched and reached over one million paying members. Russell has made personal investments in over forty technology start-ups.
He earned his BS from the Massachusetts Institute of Technology in Physics in 1984 and an MBA from Harvard University where he was a Baker Scholar in 1989.
Ned Scheetz founded Aphelion Capital in 2005 and has over 20 years of healthcare investing experience. Prior to forming Aphelion, Ned was a Partner and Managing Director with Piper Jaffray Ventures (PJV), focusing on investments in emerging medical technology companies. Ned joined PJV from Janus Capital, where he was a Senior Research Analyst covering both healthcare and internet investments. Before beginning his investment career, Ned worked in various product management roles with a subsidiary of Eastman Kodak and in sales and marketing with Kraft General Foods. Ned has served on numerous private company boards over his career. He currently serves on the Board of Directors for Aardvark Medical, ClearFlow, CyMedica, Explorer Surgical, Mercator Medsystems, and Palo Alto Health Sciences.
Ned is a graduate of Colby College, Duke University’s Fuqua School of Business, and was a post-graduate scholar at Oxford University. Ned holds the CFA designation, and is an advisory board member with the Center for Medical Device Innovation, and on the business advisory board of The Epilepsy Therapy Development Project.
Jonathan MacQuitty focuses on life science and healthcare investments at Lightspeed. Jonathan has spent over 30 years in life science companies and in the venture capital sector that finances them. He was formerly a partner at Abingworth, a trans-Atlantic life science venture capital firm, heading up the firm’s West Coast office. Most recently he was the founding CEO of Forty Seven Inc, an immuno-oncology company based in Menlo Park, CA. Jonathan serves on the board of a number of Lightspeed companies and is Chairman of Personalis, which uses human genomic analysis for cancer research and treatment. He has also served on the Board of the Biotechnology Industry Organization (BIO).
Jonathan has an MA in Chemistry from Oxford University, a PhD in Chemistry from the University of Sussex, and an MBA from Stanford University.
Amy serves as CEO, Hospital Division, and Senior Vice President, Integrated Care Delivery, at Atlantic Health System, a $2.8 billion health care organization based in Morristown, New Jersey. Amy is a strategic leader with an impressive background in finance and operations, clinical quality and academic medicine, and health policy and governance. She has a strong track record of identifying opportunities for growth and innovation, as well as substantial experience improving outcomes, lowering costs, transitioning to value-based payments, and implementing population health strategies.
Prior to Atlantic Health System, Amy served as Executive Vice President for LifeBridge Health in Baltimore, a $1.9 billion health care system, and president of Sinai Hospital in Baltimore, Maryland.
Amy earned her B.A. in Communications from the University of Minnesota, and her M.S. in Health Services Administration from Barry University in Miami.
Debra is founding President and CEO of Palo Alto Health Sciences. Since joining PAHS in 2013, Debra has grown the company by establishing relationships with leading Payers and Employers while overseeing the development and launch of the next generation Freespira treatment for panic. She has led the programs to expand PAHS’ evidence base with clinical trials for PTSD and adolescents. Debra brings a unique blend of experience to her role at PAHS, having both successfully led early stage ventures and with her expertise in respiratory physiology.
Debra is an experienced healthcare CEO with a passion for companies that develop products and services to improve people’s lives. She has broad operational and leadership roles in start-ups, corporate and nonprofit organizations. Debra has a successful record of fundraising from venture capital, angel investors and non-profit donors and significant experience working with government agencies, such as FDA and CMS, in overcoming regulatory & reimbursement obstacles. Previously, Debra worked with Exploramed, a Bay Area incubator, to develop a women’s health product. From 2001-2010, Debra was founding President, CEO and Board member of Novasys Medical where she led the development, launch and commercialization of the Renessa® treatment for female stress urinary incontinence. Prior to Novasys, Debra was Vice President and General Manager at Tyco Inc. (Mallinckrodt, Nellcor Puritan Bennett, Nellcor). Early in her career Debra was Assistant Director of Respiratory Care at Loyola University Medical Center in Chicago.
Debra holds a B.A. in Applied Behavioral Sciences, an MBA and R.R.T credentials, as well work at Stanford’s executive management programs. She has been a guest entrepreneur for 5 years as part of an HBS case study, and supports entrepreneurs through her work with Astia and with CSweetner as a mentor to female executives.
Dr. Harris is currently Chief Executive Officer and Managing Partner of Vesalius Ventures, Inc., a venture capital firm, that invest in early to mid stage Healthcare technologies and companies. As CEO, he was responsible for managing a portfolio of private assets of early and mid- stage venture investments and operating companies. Dr. Harris led Series C financing round for Palo Alto Health Sciences, and he is a formal Board Observer.
He is a member of the Board of Directors for U.S. Physical Therapy (Nasdaq: USPH), JSA Health, and Monebo Technologies. Dr. Harris serves as a Board of Trustees for Salient Midstream & MLP Fund and Salient MF Trust, and Barings Fund & Trust. In addition, he is on the Board for the Texas Medical Center, HealthConnect, National Math and Science Initiative, and the Harris Foundation.
Dr. Harris was at NASA for ten years, where he conducted research in musculoskeletal physiology and clinical investigations of space adaptation and developed in-flight medical devices to extend Astronaut stays in space. A veteran astronaut for over twenty years, he has logged more than 438 hours and traveled over 7.2 million miles in space.
He earned a Bachelor of Science in Biology from the University of Houston, a Master of Medical Science from the University of Texas Medical Branch at Galveston, a Master of Business Administration (MBA) from the University of Houston and a Doctorate of Medicine from Texas Tech University School of Medicine. He completed a Residency in Internal Medicine at the Mayo Clinic, a National Research Council Fellowship in Endocrinology at the NASA Ames Research Center and trained as a Flight Surgeon at the Aerospace School of Medicine, Brooks Air Force Base. He is also a licensed private pilot and certified scuba diver.